Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy

Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy - Efficacy of mirabegron in patient treathed with brachytherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022613

Enrollment

240

Registered

2016-07-01

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Treatments were administered once daily (tamsrosin 0.2mg) during 12 months after low-dose-rate brachytherapy Treatments were administered once daily (mirabegron 50mg) during 3 months after low-dose-ra

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: patients who underwent low-dose-rate brachytherapy

Exclusion criteria

Exclusion criteria: considered unsuitable for the trial by doctors residual urine volume greater than 100 ml Qmax less than 5 ml per second contraindicated to medication with mirabegron history of urinary retention performance of clean intermittent catheterization

Design outcomes

Primary

Measure	Time frame
the change from baseline to three months later after brachytherapy in mean volume voided per micturition	—

Secondary

Measure	Time frame
the change from baseline to three months later after brachytherapy in IPSS,OABSS, and EPIC the change from baseline to three months later after brachytherapy in maximum urinary flow rate, residual urine volume, and mean number of micturitions per 24 hours.	—

Countries

Japan

Contacts

Public ContactYasushi Nakai

Nara Medical University Department of Urology

nakaiyasushi@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026